Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.60 |
| ▸ | HTR2A | P28223 | 6/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410942 | 0.93 | HRH1 (0.58) | HRH1HTR2ASIGMAR1GRM2GRM3 | |
| SCHEMBL5412370 | 0.91 | HRH1 (0.56) | HRH1HTR2ASIGMAR1GRM2GRM3 | |
| SCHEMBL1884939 | 0.89 | LMNA (0.59) | HRH1HTR2ASIGMAR1GRM2GRM3 | |
| SCHEMBL21855514 | 0.88 | CYP19A1 (0.51) | HRH1HTR2ASIGMAR1ALDH1A1LMNA | |
| SCHEMBL128570 | 0.84 | HRH1 (0.56) | HRH1HTR2ASIGMAR1TRPA1ALDH1A1 | |
| SCHEMBL9073997 | 0.84 | HRH1 (0.71) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL2015445 | 0.83 | ALDH1A1 (0.57) | HRH1HTR2ASIGMAR1GRM2GRM3 | |
| SCHEMBL15355244 | 0.83 | RIPK1 (0.55) | TRPA1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2316371 | 0.83 | RIPK1 (0.55) | TRPA1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6520180 | 0.83 | TRPA1 (0.44) | HRH1HTR2ATRPA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322345-A | High-molecular-weight poly-delta-caprolactone and preparation method and application thereof | 南京先进生物材料与过程装备研究院有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-117186129-A | Method for preparing cis-allyl borate and allyl alcohol from cis/trans conjugated diene mixture | 成都理工大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-113425722-A | Bitter taste receptor agonist and its application in preventing and treating SARS-CoV-2 related infectious disease | 上海市浦东新区公利医院(第二军医大学附属公利医院) | 2021-09-24 | — | — | CN | disclosed |
| WO-2021103059-A1 | USE OF AROMATIC ALCOHOL AS SILK FIBROIN INDUCER AND METHOD FOR TREATING SILK FIBROIN | 苏州丝美特生物技术有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021104509-A1 | METHOD FOR TREATING SILK FIBROIN WITH AROMATIC ALCOHOL AND USE THEREOF IN PREPARATION OF SILK-FIBROIN-CONTAINING MATERIAL | 苏州丝美特生物技术有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2014159251-A2 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-10-02 | — | — | WO | disclosed |
| US-7375224-B2 | Adenine modified silica-based catalyst, a process for the preparation and use there for the production of cyclic carbonates | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-05-20 | — | — | US | disclosed |
| US-7365214-B2 | Process for the preparation of cyclic carbonates | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-04-29 | — | — | US | disclosed |
| US-20070276146-A1 | Adenine modified silica-based catalyst, a process for the preparation and use there for the production of cyclic carbonates | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-11-29 | — | — | US | disclosed |
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| EP-0923575-A1 | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | Takeda Chemical Industries, Ltd. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5767129-A | TREATING CEREBROVASCULAR DISORDERS, PAIN, CEREBRAL ISCHEMIA | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998008842-A1 | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-05 | — | — | WO | disclosed |
| CN-1088577-A | Novel multi-drug resistance modifiers | VERTEX PHARMA (US) | 1994-06-29 | — | — | CN | disclosed |
| EP-0561758-A2 | Method of preparing optically active homo-beta-amino acids | MONSANTO COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
| EP-0376608-A2 | Benzamide derivatives as antiarrhythmics | ELI LILLY AND COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0115079-B1 | SUBSTITUTED 1-((3-(AMINO)-PROPOXY)-PHENYL)-1-(PHENYL)-PROPAN-1-OLS, THEIR ACID ADDITION SALTS AND QUATERNARY SALTS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1987-03-18 | — | — | EP | disclosed |
| EP-0114410-B1 | SUBSTITUTED ALPHA-(ETHYL)-ALPHA-(PHENYL)-(OMEGA-(DIALKYLAMINO)-ALKOXY)-BENZYL ALCOHOLS, THEIR ACID ADDITION SALTS AND QUATERNARY SALTS, PROCESS FOR THEIR PREPARATION, AS WELL AS MEDICINES CONTAINING THESE COMPOUNDS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-05-14 | — | — | EP | disclosed |
| EP-0115080-B1 | (OMEGA-(DIETHYLAMINO)-ALKOXY)-ALPHA-(ETHYL)-BENZHYDROL DERIVATIVES, THEIR ACID ADDITION SALTS AND QUATERNARY SALTS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276146-A1 | Adenine modified silica-based catalyst, a process for the preparation and use there for the production of cyclic carbonates | CA9, MCM5, CCNH | HRH1 412/4885HTR2A 4018/4885SIGMAR1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.